Research programme: antibacterials - Oragenics

Drug Profile

Research programme: antibacterials - Oragenics

Alternative Names: Lantibiotics; MU 1140-S; MU-1140; MU1140 analogs - Oragenics; Mutacin 1140; OG 253; OG 716

Latest Information Update: 15 Nov 2016

Price : $50

At a glance

  • Originator University of Florida
  • Developer Intrexon Corporation; Oragenics Inc
  • Class Bacteriocins; Cyclic peptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Clostridium infections

Most Recent Events

  • 23 Aug 2016 Preclinical efficacy data from a an animal model in C. difficile infections released by Oragenics
  • 09 May 2014 It is unclear whether this programme remains available for licensing, in light of Oragenics' collaborative agreement with Intrexon (http://www.oragenics.com/)
  • 15 Feb 2013 This research programme is still in preclinical development for Bacterial infections in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top